Welcome to our dedicated page for Definitive Healthcare news (Ticker: DH), a resource for investors and traders seeking the latest updates and insights on Definitive Healthcare stock.
Definitive Healthcare Corp. reports developments in healthcare market data, analytics, and commercial intelligence for organizations operating on the business side of healthcare. Its SaaS-based platform and related solutions support use cases such as market selection, go-to-market planning, provider targeting, affiliation analysis, prescription-pattern visibility, Key Opinion Leader identification, and workflow data enrichment.
Recurring news for DH includes quarterly and annual financial results, guidance commentary, customer wins and renewals across life sciences and health-system markets, expansions involving products such as Monocl and Population Intelligence, data-integration use cases, and investor conference presentations. Company updates also describe subscription revenue trends, adjusted profitability measures, cash flow, and commercial execution across new logos and existing customers.
Summary not available.
Definitive Healthcare Corp. (Nasdaq: DH) announced that CEO Jason Krantz and CFO Rick Booth will present at the J.P. Morgan 50th Annual Global Technology, Media and Communications Conference. The presentation is scheduled for May 23, 2022, at 9:20 a.m. Eastern Time. A live webcast will be accessible through their investor relations website, with a replay available for a limited time. Definitive Healthcare specializes in healthcare commercial intelligence, providing clients insights to drive success in the healthcare market.
Definitive Healthcare Corp. (Nasdaq: DH) reported a 36% year-over-year increase in first-quarter revenue, reaching $50.1 million compared to $36.9 million in Q1 2021. Despite a net loss of ($13.1) million, which is 26% of revenue, the company showed strong operational cash flow at $13.6 million, or 27% of revenue. Adjusted net income rose to $7.7 million, highlighting profitability amidst growth. Looking ahead, the company forecasts Q2 2022 revenue between $53.0 - $54.0 million, indicating continued momentum.
Definitive Healthcare Corp. (Nasdaq: DH) announced the appointment of Robert Musslewhite as the new CEO, effective August 1, 2022. Founder Jason Krantz will transition to Executive Chairman but will remain involved in the company's strategic direction. Musslewhite, previously President, has a strong SaaS and healthcare background, including experience as CEO at OptumInsight and The Advisory Board Company. He aims to leverage his expertise to further advance the company's growth. Definitive Healthcare emphasizes its commitment to healthcare commercial intelligence with nearly 3,000 customers.
Definitive Healthcare Corp. (Nasdaq: DH) announced that it will release its first quarter financial results for the period ending March 31, 2022, on May 5, 2022, after market close. A conference call and webcast will be held at 4:30 PM ET to discuss these results. Interested parties can access the audio webcast on Definitive Healthcare's Investor Relations website. A replay of the call will be available until May 19, 2022, using the provided dial-in numbers.
Definitive Healthcare (Nasdaq: DH) has launched the Passport Analytics Suite, designed to enhance the efficiency of life sciences organizations in product development and commercialization. Powered by technologies from the recently acquired Analytical Wizards, the suite includes Passport Promotional Analytics and Passport Planning & Performance. These tools enable clients to optimize brand performance, marketing strategies, and product planning by integrating diverse data sources. This innovation positions Definitive Healthcare as a leader in offering comprehensive, data-agnostic analytics solutions.
Definitive Healthcare Corp. (Nasdaq: DH) has announced its participation in two key conferences in March 2022. The company will present at the Raymond James 43rd Annual Institutional Investors Conference on March 7 at 1:05 PM ET, featuring CEO Jason Krantz and CFO Rick Booth. Additionally, they will present at the Deutsche Bank 30th Annual Media, Internet & Telecom Conference on March 14 at 10:20 AM ET, with President Robert Musslewhite and CFO Booth. Both events will be webcast live, with replays available later.
Definitive Healthcare reported a 38% increase in Q4 2021 revenue to $46.3 million, while full-year revenue grew 40% to $166.2 million. Despite a GAAP net loss of $(14.8) million in Q4, adjusted net income rose to $6.6 million. Adjusted EBITDA in Q4 was $13.1 million, or 28% of revenue. For 2022, the company projects revenue between $218 million and $222 million. Key highlights include significant new contracts with major healthcare companies and the launch of a new product, Latitude Reporting.
Definitive Healthcare (Nasdaq: DH) will report its Q4 and full year 2021 financial results on February 23, 2022, post-market close. The company will also host a conference call and webcast at 5:00 PM ET to discuss these results. Investors can access the live audio webcast via the Investor Relations website. A replay of the call will be available shortly after its conclusion and will remain accessible until March 9, 2022. Definitive Healthcare specializes in healthcare commercial intelligence, leveraging data and analytics for market success.
Definitive Healthcare (Nasdaq: DH) launched Latitude Discovery on January 25, 2022, aimed at aiding pre-commercial biopharma and medical device companies. This innovative tool allows users to perform iterative analyses of real-world data to evaluate market opportunities linked to therapy development. Latitude Discovery provides self-service access to extensive market intelligence, enabling efficient cohort creation and real-time commercial intelligence visualizations. This product is part of the Latitude Analytics Suite, enhancing companies' commercialization efforts with precise analytics.